CTN: Northern New England Node

描述（由申请人提供）：这是一份“临床试验网络（CTN）：哈佛大学北方新英格兰节点”的更新提案，提交该提案是为了响应RFA-DA-07-001“国家药物滥用治疗临床试验网络（U10）有限竞争公告”。“北方新英格兰节点（NNEN）汇集了研究专业知识，复杂的社区治疗计划（CTP），以及在不同环境和多层次护理中接受治疗的各种患者。该节点的特点是学术研究人员和社区治疗提供者之间的伙伴关系，在整个5个新英格兰州设计和实施成瘾治疗研究，以社区为基础的治疗方案。自2002年进入CTN以来，NNEN取得了突出的进展，结合了科学和行政领导以及出色的试验表现。NNEN是处方阿片类镇痛药依赖治疗多中心研究的牵头节点，并在物质使用障碍和注意缺陷多动障碍患者的两项CTN研究的开发和实施中发挥了重要的科学领导作用。NNEN成员参与CTN的4个关键国家委员会，体现了行政领导能力; NNEN是唯一一个在所有这些委员会中都有代表的节点。NNEN成员还当选为几个国家委员会和工作组的主席，在CTN同事中表现出良好的声誉。试验表现堪称典范：NNEN参与的试验和随机化的受试者比2002年进入的任何其他节点都多;在2005-2006年节点试验性能报告中，随机化的受试者数量是CTN节点平均水平的两倍多。此外，根据最新的NIDA试验进展报告，NNEN是唯一一个节点（除了2005年进入CTN的2个新节点），在该节点进入的每项试验的每项性能指标上都达到或超过预期。NNEN现金转拨方案采用了一些新的循证做法，并在区域、国家和国际上传播有关这些做法的信息。本提案突出了北方新英格兰节点自2002年9月以来在供资期间取得的成就。虽然节点取得了显著进展，但该提案还详细介绍了在更新期间加强NNEN的一些改进措施。在接下来的三年里，NNEN计划通过实施和测试最先进的药物滥用治疗干预措施，继续推进CTN的使命，以便临床项目将使用现有的最佳治疗方法，患者将从不断发展的成瘾治疗科学中充分受益。

DESCRIPTION (provided by applicant): This is a proposal for renewal of "Clinical Trials Network (CTN): Harvard University Northern New England Node," submitted in response to RFA-DA-07-001 "Announcement of a Limited Competition of the National Drug Abuse Treatment Clinical Trials Network (U10)." The Northern New England Node (NNEN) brings together research expertise, sophisticated community treatment programs (CTPs), and a wide variety of patients being treated in diverse settings and multiple levels of care. The Node is characterized by a partnership between academic researchers and community-based treatment providers throughout 5 New England states to design and implement addiction treatment studies in community-based treatment programs. The NNEN has demonstrated outstanding progress since entering the CTN in 2002, with a combination of scientific and administrative leadership and excellent trial performance. The NNEN is the Lead Node on a multi-site study of prescription opioid analgesic dependence treatment, and has played a major scientific leadership role in the development and implementation of two CTN studies of patients with substance use disorder and attention deficit hyperactivity disorder. Administrative leadership is exemplified by participation by NNEN members on the 4 key CTN national committees; the NNEN is the only Node to be represented on all of these committees. NNEN members have also been elected to chair several national committees and work groups, demonstrating their excellent reputation among their CTN colleagues. Trial performance has been exemplary: the NNEN has participated in more trials and randomized more participants than any other Node entering in 2002; and has randomized more than twice as many participants in the 2005-2006 Node Trial Performance Report than the average for a CTN Node. Moreover, according to the most recent NIDA Trial Progress Report, the NNEN is the only Node (other than the 2 new Nodes entering the CTN in 2005) to meet or exceed expectations on every performance indicator of every trial the Node has entered. NNEN CTPs have adopted a number of new evidence-based practices, and have themselves disseminated information about these practices regionally, nationally, and internationally. This proposal highlights the accomplishments of the Northern New England Node in the funding period since September 2002. While the Node has made outstanding progress, the proposal also details a number of enhancements to strengthen the NNEN during the renewal period. During the next three years, the NNEN plans to continue to advance the mission of the CTN by implementing and testing state-of-the-art drug abuse treatment interventions, so that clinical programs will use the best treatments available and patients will receive the full benefit of the evolving science of addiction treatment.